NeuBase Therapeutics, Inc. (NASDAQ: NBSE) is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of genomic loci or secondary and tertiary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.
Dr. Dietrich A. Stephan, Ph.D. (pictured below) is the Chairman & CEO, Founder of NeuBase Therapeutics, Inc. (NASDAQ: NBSE). He is an industry veteran who is considered one of the fathers of the field of precision medicine, having trained with the leadership of the Human Genome Project at the NIH and then going on to lead discovery research at the Translational Genomics Research Institute and serve as professor and chairman of the Department of Human Genetics at the University of Pittsburgh. Stephan has identified the molecular basis of dozens of genetic diseases and published extensively in journals such as Science, the New England Journal of Medicine, Nature Genetics, PNAS and Cell. In parallel, Dr. Stephan has founded or co-founded 14 biotechnology companies and has advised an additional 12 companies. These companies are backed by top-tier investors such as Sequoia Capital, KPCB, Thiel Capital, and Khosla Ventures as well as corporate partners such as Life Technologies, Pfizer, and Mayo Clinic. Dr. Stephan received his Ph.D. from the University of Pittsburgh and his B.S. from Carnegie Mellon University.
Dietrich A. Stephan, Ph.D. Chairman & CEO, Founder of NeuBase Therapeutics, Inc. (NASDAQ: NBSE)
Learn more at the NeuBase website: www.neubasetherapeutics.com
Research Coverage
Oppenheimer - Hartaj Sing — H.C. Wainwright - Raghuram Selvaraju
Chardan - Keay Nakae
BTIG - Thomas Shrader — RBC = Brian Abrahams — Guggenheim - Whitney Ijem
NeuBase Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding NeuBase Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of NeuBase Therapeutics, Inc. or its management. NeuBase Therapeutics, Inc. or Tribe Public LLC does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Recent Events
DON'T SEE YOUR CITY?